Citations (27)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Shenvi Kudchadker Gayatri, Vaishnavi Chhabra, Harish Kumar & M. Elizabeth Sobhia. (2023) Identification of prospective covalent inhibitors for SARS-CoV-2 main protease using structure-based approach. Journal of Biomolecular Structure and Dynamics 41:16, pages 7913-7930.
Read now
Read now
Ping Han, Yu Lei, Dongxiao Li, Jingmei Liu, Wei Yan & Dean Tian. (2019) Ten years of research on the role of BVES/ POPDC1 in human disease: a review. OncoTargets and Therapy 12, pages 1279-1291.
Read now
Read now
Ramiz N. Hamid, Christine S. Ahn & William W. Huang. (2019) Adverse cutaneous effects of neratinib. Journal of Dermatological Treatment 30:5, pages 487-488.
Read now
Read now
Carlos Martínez-Pérez, Arran K Turnbull & J Michael Dixon. (2019) The evolving role of receptors as predictive biomarkers for metastatic breast cancer. Expert Review of Anticancer Therapy 19:2, pages 121-138.
Read now
Read now
Isabel Echavarria, Sara López-Tarruella, Iván Márquez-Rodas, Yolanda Jerez & Miguel Martin. (2017) Neratinib for the treatment of HER2-positive early stage breast cancer. Expert Review of Anticancer Therapy 17:8, pages 669-679.
Read now
Read now
Robert Musiol. (2017) An overview of quinoline as a privileged scaffold in cancer drug discovery. Expert Opinion on Drug Discovery 12:6, pages 583-597.
Read now
Read now
Daniel Plano, Verónica Alcolea, Carmen Sanmartín & Arun K. Sharma. (2017) Methods of selecting combination therapy for colorectal cancer patients: a patent evaluation of US20160025730A1. Expert Opinion on Therapeutic Patents 27:5, pages 527-538.
Read now
Read now
Naoko Matsuda, Bora Lim, Xiaoping Wang & Naoto T. Ueno. (2017) Early clinical development of epidermal growth factor receptor targeted therapy in breast cancer. Expert Opinion on Investigational Drugs 26:4, pages 463-479.
Read now
Read now
Annemie Prové & Luc Dirix. (2016) Neratinib for the treatment of breast cancer. Expert Opinion on Pharmacotherapy 17:16, pages 2243-2248.
Read now
Read now
Articles from other publishers (18)
Mohamed Rahamathulla, Umme Hani, Ali Alqahtani, Gangadharappa. H.V, Yasmin Begum M, Mohammed Jafar, Riyaz Ali M. Osmani, Kumarappan Chidambaram, Afrasim Moin & S. J. Shankar. (2021) 23 Factorial Design and Optimization of Effervescent Floating Matrix Tablet of Neratinib. Journal of Pharmaceutical Innovation 17:4, pages 1451-1462.
Crossref
Crossref
Amandeep Thakur, Chetna Faujdar, Ram Sharma, Sachin Sharma, Basant Malik, Kunal Nepali & Jing Ping Liou. (2022) Glioblastoma: Current Status, Emerging Targets, and Recent Advances. Journal of Medicinal Chemistry 65:13, pages 8596-8685.
Crossref
Crossref
Busra Demir Cetinkaya & Cigir Biray Avci. (2022) Molecular perspective on targeted therapy in breast cancer: a review of current status. Medical Oncology 39:10.
Crossref
Crossref
Edward Woods, Dat Le, Bharath Kumar Jakka & Ashish Manne. (2022) Changing Landscape of Systemic Therapy in Biliary Tract Cancer. Cancers 14:9, pages 2137.
Crossref
Crossref
Maria G. Fencer, Catherine H. Davis & Kristen R. Spencer. (2022) Current Updates on HER2–Directed Therapies in Metastatic Colorectal Cancer. Current Colorectal Cancer Reports 18:2, pages 27-37.
Crossref
Crossref
Ming Shen Dai, Yin Hsun Feng, Shang Wen Chen, Norikazu Masuda, Thomas Yau, Shou Tung Chen, Yen Shen Lu, Yoon Sim Yap, Peter C. S. Ang, Sung Chao Chu, Ava Kwong, Keun Seok Lee, Samuel Ow, Sung Bae Kim, Johnson Lin, Hyun Cheol Chung, Roger Ngan, Victor C. Kok, Kun Ming Rau, Takafumi Sangai, Ting Ying Ng, Ling Ming Tseng, Richard Bryce, Judith Bebchuk, Mei Chieh Chen & Ming Feng Hou. (2021) Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens. Breast Cancer Research and Treatment 189:3, pages 665-676.
Crossref
Crossref
Thidarath Rattanaburee, Tanotnon Tanawattanasuntorn, Tienthong Thongpanchang, Varomyalin Tipmanee & Potchanapond Graidist. (2021) Trans-(−)-Kusunokinin: A Potential Anticancer Lignan Compound against HER2 in Breast Cancer Cell Lines?. Molecules 26:15, pages 4537.
Crossref
Crossref
Andreia Gameiro, Filipe Almeida, Catarina Nascimento, Jorge Correia & Fernando Ferreira. (2021) Tyrosine Kinase Inhibitors Are Promising Therapeutic Tools for Cats with HER2-Positive Mammary Carcinoma. Pharmaceutics 13:3, pages 346.
Crossref
Crossref
Paula Dlugosz, Magdalena Teufl, Maximilian Schwab, Katharina Eva Kohl & Johannes Nimpf. (2021) Disabled 1 Is Part of a Signaling Pathway Activated by Epidermal Growth Factor Receptor. International Journal of Molecular Sciences 22:4, pages 1745.
Crossref
Crossref
Sara El-Sahli & Lisheng Wang. (2020) Cancer Stem Cell-Associated Pathways in the Metabolic Reprogramming of Breast Cancer. International Journal of Molecular Sciences 21:23, pages 9125.
Crossref
Crossref
Yanna Mao, Kunjal Soni, Chetan Sangani & Yongfang Yao. (2020) An Overview of Privileged Scaffold: Quinolines and Isoquinolines in Medicinal Chemistry as Anticancer Agents. Current Topics in Medicinal Chemistry 20:28, pages 2599-2633.
Crossref
Crossref
Matthias Piesche, Jessica Roos, Benjamin Kühn, Jasmin Fettel, Nadine Hellmuth, Camilla Brat, Isabelle V. Maucher, Omar Awad, Carmela Matrone, Simon Gabriel Comerma Steffensen, Georg Manolikakes, Ulrike Heinicke, Kai D. Zacharowski, Dieter Steinhilber & Thorsten J. Maier. (2020) The Emerging Therapeutic Potential of Nitro Fatty Acids and Other Michael Acceptor-Containing Drugs for the Treatment of Inflammation and Cancer. Frontiers in Pharmacology 11.
Crossref
Crossref
Denis M. Collins, Neil T. Conlon, Srinivasaraghavan Kannan, Chandra S. Verma, Lisa D. Eli, Alshad S. Lalani & John Crown. (2019) Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer. Cancers 11:6, pages 737.
Crossref
Crossref
Hope S. Rugo, Jack A. Di Palma, Debu Tripathy, Richard Bryce, Susan Moran, Elizabeth Olek & Linda Bosserman. (2019) The characterization, management, and future considerations for ErbB-family TKI-associated diarrhea. Breast Cancer Research and Treatment 175:1, pages 5-15.
Crossref
Crossref
Ajaz Bulbul, Emilio Araujo-Mino & Zoneddy Ruiz Dayao. (2018) The Conundrum of Adjuvant HER2 Treatment Options. Frontiers in Oncology 8.
Crossref
Crossref
Tanveer A. Wani, Ahmed H. Bakheit, M. A. Abounassif & Seema Zargar. (2018) Study of Interactions of an Anticancer Drug Neratinib With Bovine Serum Albumin: Spectroscopic and Molecular Docking Approach. Frontiers in Chemistry 6.
Crossref
Crossref
Karl R. Sorenson, Guilherme Piovezani Ramos, Jose Caetano Villasboas Bisneto & Katharine Price. (2017) Targeted Approaches Applied to Uncommon Diseases: A Case of Salivary Duct Carcinoma Metastatic to the Brain Treated with the Multikinase Inhibitor Neratinib. Case Reports in Oncology 10:2, pages 726-731.
Crossref
Crossref
Timothy P. Heffron. (2016) Small Molecule Kinase Inhibitors for the Treatment of Brain Cancer. Journal of Medicinal Chemistry 59:22, pages 10030-10066.
Crossref
Crossref